Zoryve (roflumilast cream) is a new addition to the arsenal of non-steroidal topical therapies for mild to moderate plaque psoriasis.
Mechanism of Action:
Unlike traditional corticosteroids, Zoryve employs a unique mechanism of action by inhibiting phosphodiesterase type 4 (PDE4). This is the same target as the oral medication Otezla and the topical eczema medication Eucrisa. This targeted approach modulates intracellular cyclic adenosine monophosphate (cAMP) levels, leading to:
- Downregulation of pro-inflammatory cytokines: Th1 and Th17, key contributors to psoriatic inflammation.
- Reduction of keratinocyte proliferation: A hallmark feature of psoriatic plaques.
- Modulation of immune cell function: Suppressing activation and migration of inflammatory cells.
Clinical trials demonstrate Zoryve’s significant efficacy in achieving:
- Improvements in PASI scores: Studies reported PASI 75 response rates exceeding 50% within 8 weeks of daily application.
- Enhanced skin clearance: Up to 25% of patients achieved clear or almost clear skin by week 8.
- Fast symptom relief: Improvements in itching and scaling observed within 2 weeks.
Importantly, long-term steroid-associated risks like skin thinning and atrophy are not observed with Zoryve.
Potential Value for Dermatologists:
Zoryve offers several advantages for managing plaque psoriasis:
- Effective alternative for steroid-averse patients: Provides relief without the potential side effects of prolonged corticosteroid use.
- Suitable for intertriginous areas: Safe and effective application in delicate areas like folds and creases.
- Offers convenient once-daily dosing: Promotes patient adherence and treatment success.
- Potential for combination therapy: May complement other psoriasis treatments for synergistic effects.
Zoryve (roflumilast cream) represents a valuable new topical option for mild to moderate plaque psoriasis. Its unique mechanism of action, promising efficacy, and favorable safety profile warrant further exploration and integration into individualized treatment plans.
Additional Resources:
- Zoryve website: https://www.zoryve.com/